Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Laquinimod (ABR-215062) sodium is a carboxamide derivative administered orally that serves as a powerful immunomodulator, designed to prevent inflammation and neurodegeneration within the central nervous system. This compound effectively diminishes the activation of astrocytic NF-κB, offering protection against Cuprizone-induced demyelination. It shows promise for the treatment of both relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS), in addition to its potential applications in the study of neurodegenerative diseases [1] [2] [3] [4].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 2,140.00 | |
50 mg | 6-8 weeks | $ 2,785.00 | |
100 mg | 6-8 weeks | $ 3,520.00 |
Description | Laquinimod (ABR-215062) sodium is a carboxamide derivative administered orally that serves as a powerful immunomodulator, designed to prevent inflammation and neurodegeneration within the central nervous system. This compound effectively diminishes the activation of astrocytic NF-κB, offering protection against Cuprizone-induced demyelination. It shows promise for the treatment of both relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS), in addition to its potential applications in the study of neurodegenerative diseases [1] [2] [3] [4]. |
In vitro | Laquinimod sodium effectively counters Experimental Autoimmune Encephalomyelitis (EAE) and suppresses deleterious T cell immune responses, primarily through direct action on myeloid Antigen-Presenting Cells (APC). It modifies myeloid APC subsets, curbing the polarization of Th1 and Th17 in myelin-specific T cells, and induces type II (M2) monocytes which reverse established EAE [1]. Additionally, Laquinimod modulates both the phenotype of B cells in healthy donors and the expression of regulatory markers in B cells of patients with Relapsing-Remitting Multiple Sclerosis (RRMS), alongside reducing IFNγ cytokine levels in CD4+ T cells [2]. |
In vivo | Laquinimod sodium treatment suppresses the ability of donor myelin-specific T cells to transfer Experimental Autoimmune Encephalomyelitis (EAE) to naive recipient mice. It also modifies myeloid antigen-presenting cell (APC) subpopulations in vivo, characterized by reduced numbers of CD11c+ CD11b+ CD4+ dendritic cells (DC) and increased levels of CD11b hi Gr1 hi monocytes [1]. |
Molecular Weight | 378.79 |
Formula | C19H16ClN2NaO3 |
CAS No. | 248282-07-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Laquinimod sodium 248282-07-7 inhibitor inhibit